The Russian Ministry of Health, the Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announce that Sputnik Light, a single dose COVID-19 vaccine, has received authorization for use in Russia.
Article continues below
>
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of the Sputnik V coronavirus vaccine.
The single dose Sputnik Light vaccine demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered. An efficacy level of near 80% is higher than that of many two-dose vaccines.
The efficacy rate was calculated based on data obtained from Russians vaccinated with a single injection, having not received the second one for any reason during the mass vaccination program between December 5, 2020 and April 15, 2021.
The infection rate among vaccinated subjects from the 28th day from the date of the injection was only 0.277%. Over the same period, the infection rate among the unvaccinated adult population was 1.349%.
The following formula was used to calculate the vaccine's efficacy:
Phase I/II Safety and Immunogenicity Study of the single dose Sputnik Light vaccine was initiated in January 2021, and the interim results were received on March 10, 2021:
• The results demonstrated that the vaccine can elicit the development of antigen specific IgG antibodies in 96.9% of volunteers on the 28th day after immunization;
• Virus-neutralizing antibodies developed in 91.67% of volunteers on the 28th day post immunization.
• Cellular immune response against the S Protein of SARS-CoV-2 developed in 100% of volunteers;
• No serious adverse events were registered after vaccination with Sputnik Light;
• The immunization of individuals with pre-existing immunity against SARS-CoV-2 with Sputnik Light can elicit an increase of the level of IgG antibodies by more than 40x in 100% of volunteers on the 10th day after immunization;
• Sputnik Light demonstrated safety for all subjects, including those with pre-existing immunity to SARS-CoV-2.
On February 21, 2021 the Gamaleya Center and RDIF launched a global efficacy study of Sputnik Light. The Phase III clinical study involving 7,000 people is conducted in multiple countries including Russia, the UAE, Ghana and others. The interim results are expected in May 2021.
The Sputnik Light vaccine is based on a well-studied human adenoviral vector platform that has proven to be safe and effective.
The cost of the Sputnik Light vaccine globally will be less than $10, while it has simple storage requirements, at +2 +8, which provide for easy logistics.
The one shot regimen allows for the vaccination of large groups of the population in a short time, helping to speed up the fight against the pandemic during the acute phase.
Alexander Gintsburg, Director of the Gamaleya National Research Center of Epidemiology and Microbiology, said: “Sputnik Light will help to prevent the spread of coronavirus through the faster immunization of larger population groups, as well as supporting high immunity levels in those who have already been infected previously. Sputnik Light offers strong value in initial vaccination and re-vaccination, as well as boosting efficacy when taken in combination with other vaccines.†■